diabetic nephrology
Conditions
Interventions
Group 1:Placebo combined with losartan
Sponsors
Shanghai Sixth People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Individuals who meet all the following inclusion criteria are enrolled in the trial: 1.Aged >= 18 and 30 mg/g and = 60 mL/min/1.73 m2 (CKD-EPI formula); 6.Before screening, blood pressure is within the following range: Blood pressure: systolic blood pressure 110-160 mmHg, diastolic blood pressure 60-100 mmHg; 7.Participants should sign the informed consent before the commencenent of the study voluntarily, understand the procedures and methods of the study, and are willing to complete this study in strict accordance with the clinical research protocol.
Exclusion criteria
Exclusion criteria: Individuals who meet one of the following conditions should not be enrolled in the trial: 1.Type 1 diabetes; 2.Serum potassium >= 5.5 mmol/l after repeatedly potassium lowering treatment, or serum potassium 3 fold)or other known acute/chronic active hepatitis and cirrhosis during screening; 4. Acute urinary tract infection within 2 weeks before randomization; 5. Other chronic kidney diseases (such as glomerulonephritis, chronic pyelonephritis, ischemic kidney disease, etc.) during screening; 6.Blood pressure <= 110/60mmHg before screening; 7.History of severe acute diabetes complications (ketoacidosis, lactic acidosis, hypertonic non ketotic diabetes coma, hypoglycemic coma) within 6 months before screening; 8.Severe comorbid diseases: acute coronary syndrome (myocardial infarction, unstable angina pectoris), heart failure (NYHA III-IV), or surgical history for heart related diseases, stroke or transient ischemic attack within 3 months before screening; 9.History of mental illness or language barriers and are unable to cooperate or unwilling to cooperate; 10.History of rheumatic diseases (such as systemic lupus erythematosus); 11.History of malignant tumors or receiving antineoplastic drugs and/or surgical treatment within 5 years; 12.History of organ transplantation; 13.Allergic to the test drugs; 14.Those who are participating in other drug clinical trials or have participated in other drug trials within 3 months before screening (enrolled in the group and treated with test drugs); 15.Pregnant or lactating female patients; 16.Using two or more anticoagulant or antiplatelet drugs; 17.Other conditions that are not suitable for this test judged by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| UACR; | — |
Secondary
| Measure | Time frame |
|---|---|
| TCM syndrome score;uric microalbumin in 24h;urinary protein in 24h;eGFR; | — |
Countries
China
Contacts
Public ContactGui Dingkun
Shanghai Sixth People's Hospital
Outcome results
None listed